Clayton researchers have developed the following transgenic mice that are available for non-exclusive licensing: CRFR1 knock-out CRFR2 knock-out Urocortin knock-out ACC2 knock-out
Hide Details

Methods for treating or preventing tauopathies by modulating CRF receptor signaling. Accumulation of hyperphosphorlyated tau protein in the CNS may be reduced by administration of CRF-R1 selective antagonists and/or CRF-R2 selective agonists. For example, in some aspects, methods for preventing the onset of Alzheimer’s disease by administration of CRF-R1 selective antagonist are provided.
Reference# CLFR285
Application# US12/663805
Hide Details

A method of preparing neural precursor cells by exposing pluripotent stem cells or neural stem cells to a differentiation agent. The agent is a pyridine analog, which in preferred embodiments is a phenylethynyl-substituted or phenylazo-substituted pyridine. In other embodiments, a method of enhancing neural precursor cell survival is provided in which the survival is enhanced by exposure to the pyridine analog. In further embodiments, a method of preparing neuronal cells is provided in which pluripotent or neural stem cells exposed to the pyridine analog are then incubated without the pyridine analog, resulting in differentiation into neurons, astrocytes and oligodendrocytes.
Reference# CLFR286
Application# US12/747116
Hide Details

Cripto is a recognized oncogene that plays a key role in cancer. Antagonists of Cripto, such as Alk4-L75A and Cripto7Grp78 inhibitors are excellent therapeutic candidates to treat solid tumors.
Hide Details

Antibodies with an engineered Fc domain to specifically enhance therapeutic effector function.
Application# US12/112971 and US12/827386
Hide Details

siRNA and antibodies to the SRPX2 gene and gene product for the treatment of angiogenic disorders, including cancer.
Reference# CLFR311
Application# PCT/US2009/035831, US 12/921284
Hide Details

Chimeric polypeptides with cell targeting moieties and signal transduction factors. For example fusion proteins between antibody targeting molecules and apoptosis inducing factors, such as granzyme B and pro-apoptotic Bcl-2 family members. These chimeric molecules may be used in the treatment of cell proiferative diseases such as cancer.
Reference# CLFR012
Patent# US7101977, US7371723, US7759091, US12/788005, CA2454048, AU2002327310, NZ530582, RU2319709, IL159894, ZA2004/0228
Hide Details

Compositions and Systems for Regulation of Genes. Vectors and methods for controlled and/or inducible expression of small interfering RNA.
Reference# CLFR023
Application# US2007/0196922
Hide Details

The Eclonal technology is an integrated platform for the isolation, engineering and expression of IgG antibodies in bacteria.
Hide Details

We offer molecularly characterized novel major immunoreactive proteins of E. canis and E. chaffeensis, which are considered to be excellent candidates for immunodiagnostic and vaccine development.
Hide Details

Methods of treating or preventing eye disease in a subject, involving administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a polypeptide having a vascular endothelial targeting amino acid sequence and a cytotoxic amino acid sequence are disclosed. For example, the vascular endothelial targeting amino acid sequence may be a VEGF sequence, such as a VEGF121 sequence. Exemplary cytotoxic amino acid sequences include toxin sequences, such as gelonin, pro-apoptotic sequences, and anti-angiogenic sequences. The eye disease may be any eye disease, such as an eye disease associated with choroidal neovascularization, retinal neovascularization, iris neovascularization, or corneal neovascularization.
Reference# CLFR251
Application# 11/414782
Hide Details

RTEF-1 Variants and the Use Thereof for Inhibition of Angiogenesis. Dominant negative (DN) variants of transcriptional enhancer factor 1-related (RTEF-1) are described. DN RTEF-1 polypeptides may be directly targeted to cells or delivered in nucleic acid expression vectors to alter cellular transcription. Methods for inhibiting VEGF production and thereby treating angiogenic disorders such as cancer are described. For example, in certain aspects, DN RTEF-1 may be used to treat angiogenic disorders of the eye such as age related macular degeneration (AMD).
Reference# CLFR275
Application# PCT/US2008/066058, US 12/134626
Hide Details

Low molecular weight Cyclin E (LMW-E) is tumorigenic and can be used as a prognostic and predictive marker for responding to Her-2 targeted therapy in breast cancer patients. LMW-E may be specifically targeted for tumor therapy and/or used to personalize a cancer therapy.
Reference# CLFR335
Application# PCT/US2010/026781
Hide Details